Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis

Abstract Background Breast cancer is one of the most common malignancies in women worldwide, and one of the leading causes of cancer-related death. Programmed cell death 1 (PD-1) and its ligand (PD-L1) are key physiologic suppressors of the cytotoxic immune reaction. Some authors advocate that PD-L1...

Full description

Bibliographic Details
Main Authors: Isnard Elman Litvin, Machline Paim Paganella, Eliana Marcia Wendland, Adriana Vial Roehe
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Systematic Reviews
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13643-020-01306-9
id doaj-d65a2f0275bd4a0d9cb0b85f9be22946
record_format Article
spelling doaj-d65a2f0275bd4a0d9cb0b85f9be229462020-11-25T02:06:32ZengBMCSystematic Reviews2046-40532020-03-01911710.1186/s13643-020-01306-9Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysisIsnard Elman Litvin0Machline Paim Paganella1Eliana Marcia Wendland2Adriana Vial Roehe3Graduate Program in Pathology, Federal University of Health Sciences of Porto AlegreInstituto de Pesquisas em Saúde (IPS), University of Caxias do Sul –UCSFederal University of Health Sciences of Porto Alegre, Community Health DepartmentGraduate Program in Pathology, Federal University of Health Sciences of Porto AlegreAbstract Background Breast cancer is one of the most common malignancies in women worldwide, and one of the leading causes of cancer-related death. Programmed cell death 1 (PD-1) and its ligand (PD-L1) are key physiologic suppressors of the cytotoxic immune reaction. Some authors advocate that PD-L1 expression may help in breast cancer prognosis. Methods We will conduct a systematic review of observational or interventional studies evaluating the prognostic ability of PD-L1 expression levels in predicting positive clinical outcomes in Human Breast Cancer. A sensitive search strategy will be employed in MEDLINE, EMBASE, LILACS, The Grey Literature Report, OpenGrey, OAIster, and Cochrane CENTRAL. Two reviewers will independently screen all identified references for eligibility and extract data. The outcomes evaluated will be Overall Survival, Breast Cancer-specific Survival, Disease-free Survival, Recurrence-free Survival, Positive Lymph Node, and Distant Metastasis. The outcomes will be extracted directly from the studies, if available. Methodological quality and bias of included studies will be assessed using a standardized checklist and overall quality of evidence will be assessed through the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. If meta-analysis is possible, the measures of association will be calculated using bivariate random-effects models. Statistical heterogeneity will be evaluated with I 2 statistics and explored through sensitivity analysis. Discussion Immunomodulation seems to be a promising strategy in solid tumors. Breast cancer is the most common malignancies in women worldwide, and one of the leading causes of cancer death. PD-1 and PD-L1 are key physiologic suppressors of the cytotoxic immune reaction. Trial registration Systematic review registration: CRD42019121118 (PROSPERO)http://link.springer.com/article/10.1186/s13643-020-01306-9PD-L1Human Breast CancerSystematic ReviewMeta-analysisProtocol
collection DOAJ
language English
format Article
sources DOAJ
author Isnard Elman Litvin
Machline Paim Paganella
Eliana Marcia Wendland
Adriana Vial Roehe
spellingShingle Isnard Elman Litvin
Machline Paim Paganella
Eliana Marcia Wendland
Adriana Vial Roehe
Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis
Systematic Reviews
PD-L1
Human Breast Cancer
Systematic Review
Meta-analysis
Protocol
author_facet Isnard Elman Litvin
Machline Paim Paganella
Eliana Marcia Wendland
Adriana Vial Roehe
author_sort Isnard Elman Litvin
title Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis
title_short Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis
title_full Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis
title_fullStr Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis
title_full_unstemmed Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis
title_sort prognosis of pd-l1 in human breast cancer: protocol for a systematic review and meta-analysis
publisher BMC
series Systematic Reviews
issn 2046-4053
publishDate 2020-03-01
description Abstract Background Breast cancer is one of the most common malignancies in women worldwide, and one of the leading causes of cancer-related death. Programmed cell death 1 (PD-1) and its ligand (PD-L1) are key physiologic suppressors of the cytotoxic immune reaction. Some authors advocate that PD-L1 expression may help in breast cancer prognosis. Methods We will conduct a systematic review of observational or interventional studies evaluating the prognostic ability of PD-L1 expression levels in predicting positive clinical outcomes in Human Breast Cancer. A sensitive search strategy will be employed in MEDLINE, EMBASE, LILACS, The Grey Literature Report, OpenGrey, OAIster, and Cochrane CENTRAL. Two reviewers will independently screen all identified references for eligibility and extract data. The outcomes evaluated will be Overall Survival, Breast Cancer-specific Survival, Disease-free Survival, Recurrence-free Survival, Positive Lymph Node, and Distant Metastasis. The outcomes will be extracted directly from the studies, if available. Methodological quality and bias of included studies will be assessed using a standardized checklist and overall quality of evidence will be assessed through the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. If meta-analysis is possible, the measures of association will be calculated using bivariate random-effects models. Statistical heterogeneity will be evaluated with I 2 statistics and explored through sensitivity analysis. Discussion Immunomodulation seems to be a promising strategy in solid tumors. Breast cancer is the most common malignancies in women worldwide, and one of the leading causes of cancer death. PD-1 and PD-L1 are key physiologic suppressors of the cytotoxic immune reaction. Trial registration Systematic review registration: CRD42019121118 (PROSPERO)
topic PD-L1
Human Breast Cancer
Systematic Review
Meta-analysis
Protocol
url http://link.springer.com/article/10.1186/s13643-020-01306-9
work_keys_str_mv AT isnardelmanlitvin prognosisofpdl1inhumanbreastcancerprotocolforasystematicreviewandmetaanalysis
AT machlinepaimpaganella prognosisofpdl1inhumanbreastcancerprotocolforasystematicreviewandmetaanalysis
AT elianamarciawendland prognosisofpdl1inhumanbreastcancerprotocolforasystematicreviewandmetaanalysis
AT adrianavialroehe prognosisofpdl1inhumanbreastcancerprotocolforasystematicreviewandmetaanalysis
_version_ 1724933445485854720